Evonik completes acquisition of BI’s Resomer business

Published: 1-Mar-2011
Ingredients Finance

Enters new pharmaceutical application areas


Evonik Industries formally acquired the Resomer business of Boehringer Ingelheim today (1 March).

The German pharmaceutical firm has transferred its portfolio of standard and customised polymers used in medical applications and pharmaceutical formulations to Evonik’s Pharma Polymers Business Line. Based on lactic and glycolic acids, these polymers are biodegradable in the body.

The companies have agreed not to disclose details of the purchase price.

Klaus Engel, chairman of Evonik Industries, said: ‘This transaction strengthens our position as a strategic partner to the pharmaceuticals industry. We view the pharmaceuticals market as a strategic core business in which we’ll continue to grow, both organically and through acquisitions.’

  • Companies:
  • Boehringer Ingelheim
  • Evonik
See more

You may also like

Ingredients

Therapeutic: spesolimab for generalised pustular psoriasis

Read more
Generalised pustular psoriasis (GPP) is a rare neutrophilic skin disease that’s potentially life threatening and is clinically distinct from the more common plaque psoriasis

Trending Articles

  1. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  2. The evolution of the pharma industry: From reactive to disruptive Globally, the pharma industry has witnessed waves of changes during the last century; we have evolved, writes Ajit Kanetkar, Head, Process Technology, ACG, from maintaining a conservative outlook and being solely reactive to disease and healthcare issues to having a radical and disruptive approach
  3. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  4. Highly potent APIs: Hazards in classification and handling This variability and subjective nature of classification means that the OEL is best considered as a tool for site risk management teams
  5. Small molecules: big market opportunities The rapid rise of biologic drugs in recent years has been accompanied by a market narrative that suggests that innovation and new treatments will be fuelled by breakthroughs in this area, leading to a decline in the small molecule pipeline. This is far from true, notes Kevin Cook, Chief Executive Officer at Sterling Pharma Solutions; both are increasing and small molecule drugs continue to be a mainstay of many drug development portfolios

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Ingredients

Therapeutic: spesolimab for generalised pustular psoriasis

Generalised pustular psoriasis (GPP) is a rare neutrophilic skin disease that’s potentially life threatening and is clinically distinct from the more common plaque psoriasis
Finance

Evonik introduces three product lines for health care business

This structural shift is aimed to further transitions the health care business line into a system solutions partner for the pharmaceutical and biotech industries
Manufacturing

Evonik invests in 3D printed tablet tech for controlled delivery

Laxxon Medical’s 3D screen printing technology allows tablets to be constructed in layers of API or inert ingredients
Manufacturing

Evonik increases plant-derived cholesterol supply

The ingredient is used in the manufacture of mRNA vaccines and gene therapies
Research & Development

BioMed X and Boehringer Ingelheim initiate brain sensor project

Two projects are already underway between the research partners, including one in immunology and one in neuroscience
Research & Development

Boehringer Ingelheim and OBT advance oncology candidate

The Boehringer Ingelheim drug candidate was discovered in a partnership with Oxford BioTherapeutics and enabled by Oxford BioTherapeutics’ proprietary OGAP target discovery platform
Finance

Nanoform to initiate PoC studies for Boehringer Ingelheim projects

The two companies have executed a master services agreement to initiate projects in the pre-clinical early development space
Subscribe now